Evaluation of the clinical efficacy of marbofloxacin (Zeniquin) tablets for the treatment of canine pyoderma: an open clinical trial |
| |
| Authors: | Manon Paradis L Abbey† B Baker‡ M Coyne§ M Hannigan¶ D Joffe B Pukay†† A Trettien‡‡ S Waisglass§§ J Wellington¶¶ |
| |
| Institution: | Department of Clinical Sciences, Facultéde médecine vétérinaire, Universitéde Montréal, CP 5000, St-Hyacinthe, Québec, Canada, J2S 7C6 ;General Veterinary Hospital, Edmonton, Alberta, Canada ;Baker Animal Clinic, Whitby, Ontario, Canada ;Animal Health Group, Pfizer Inc., New York, USA ;Properties Animal Clinic, Calgary, Alberta, Canada ;Landing Animal Clinic, Calgary, Alberta, Canada ;Bayview Animal Hospital, Ottawa, Ontario, Canada ;Pfizer Animal Health, Exton, PA, USA ;Doncaster Animal Clinic, Thornhill, Ontario, Canada ;Veterinary Referral Clinic of Mississauga, Ontario, Canada |
| |
| Abstract: | The efficacy and field safety of marbofloxacin (Zeniquin) for the treatment of superficial and deep bacterial pyoderma were evaluated. Seventy‐two dogs were treated with 2.75 mg kg?1 of marbofloxacin orally once daily for 21 or 28 days. Sixty‐two dogs (86%) had superficial pyoderma and 10 (14%) had deep pyoderma. A history of prior pyoderma was reported in 39/72 dogs. Pretreatment aerobic bacteriologic cultures of skin lesions were performed in 47 cases and the predominant pathogen isolated was Staphylococcus intermedius. Treatment was successful in 62/72 (86.1%) dogs, improvement was noted in 6/72 (8.3%) dogs and treatment failed in 4/72 (5.6%) dogs. Adverse effects associated with treatment included listlessness, anorexia, vomiting, soft stool, flatulence and polydipsia; these adverse effects were seen in only 6/81 dogs. Marbofloxacin was safe and effective for the treatment of superficial and deep pyoderma in dogs at the dosage used in this study. |
| |
| Keywords: | bacterial pyoderma dogs fluoroquinolone marbofloxacin |
|
|
